The placebo treatments in neurosciences

@article{Diederich2008ThePT,
  title={The placebo treatments in neurosciences},
  author={N. Diederich and C. Goetz},
  journal={Neurology},
  year={2008},
  volume={71},
  pages={677 - 684}
}
Placebo (PL) treatment is a method utilized as a control condition in clinical trials. A positive placebo response is seen in up to 50% of patients with Parkinson disease (PD), pain syndromes, and depression. The response is more pronounced with invasive procedures or advanced disease. Physiologic and biochemical changes have been studied in an effort to understand the mechanisms underlying placebo-related clinical improvement. In PD, objective clinical improvements in parkinsonism correlate… Expand
The subthalamic nucleus and the placebo effect in Parkinson's disease.
The study of the placebo effect, or response, is related to the investigation of the psychologic component of different therapeutic rituals. The high rate of placebo responses in Parkinson's diseaseExpand
Placebo Effects in Traumatic Brain Injury.
TLDR
Several of the primary psychological processes driving placebo effects as well as placebo neurobiology are examined, to explore whether something inherent in TBI makes it particularly responsive to placebos. Expand
Placebo Effects in Neurological Diseases
TLDR
This paper reviews recent articles about placebo effect, with an emphasis on its importance in several neurological conditions (Parkinson's disease, neuropathic pain, headache, multiple sclerosis, epilepsy), and intends to offer new insights on this major topic. Expand
Brain networks predicting placebo analgesia in a clinical trial for chronic back pain
TLDR
The findings indicate that placebo response can be identified a priori at least in CBP, and that neuronal population interactions between prefrontal cognitive and pain processing regions predetermine the probability of placebo response in the clinical setting. Expand
Nocebo and lessebo effects.
TLDR
Recognizing the potential impact of nocebo and lessebo effects, mitigating strategies are in development with application to clinical research and clinical practice, such as a contextualized informed consent process, alternative study designs and enhancement of patient-physician communication. Expand
Nocebo and lessebo effects
TLDR
Recognizing the potential impact of nocebo and lessebo effects, mitigating strategies are in development with application to clinical research and clinical practice, such as a contextualized informed consent process, alternative study designs and enhancement of patient-physician communication. Expand
Psychiatric Care in Parkinson’s Disease
  • R. Quelhas
  • Medicine
  • Journal of psychiatric practice
  • 2013
TLDR
Therapeutic approaches to the treatment of PD and its associated psychiatric symptoms must be individualized and may involve a combination of antiparkinson drugs, psychopharmacological treatment, and/or psychotherapeutic interventions. Expand
Pain Modulation: From Conditioned Pain Modulation to Placebo and Nocebo Effects in Experimental and Clinical Pain.
TLDR
A greater understanding of the role of pain modulation in various pain states can help characterize the manifestation and development of chronic pain and assist in predicting the response to pain-relieving treatments. Expand
The role of placebo in the diagnosis and treatment of functional neurologic disorders.
TLDR
In this chapter, cases describing placebo as therapy for psychogenic disorders and the challenges related to embedded Cartesian beliefs in Western medicine are discussed and the legitimate ethical reservations against placebo therapy are reviewed. Expand
Placebo Intervention Enhances Reward Learning in Healthy Individuals
TLDR
The results indicate that the placebo response is able to enhance reward learning in healthy individuals, opening up exciting avenues for future research in placebo effects on other cognitive functions. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 63 REFERENCES
Understanding the Placebo Effect: Contributions from Neuroimaging
TLDR
Evidence from positron emission tomography and functional magnetic resonance imaging studies suggests that expectations of symptom improvement are driven by frontal cortical areas, particularly the dorsolateral prefrontal, orbitofrontal, and anterior cingulate cortices. Expand
The functional neuroanatomy of the placebo effect.
TLDR
The common pattern of cortical glucose metabolism increases and limbic-paralimbic metabolism decreases in placebo and fluoxetine responders suggests that facilitation of these changes may be necessary for depression remission, regardless of treatment modality. Expand
Changes in brain function of depressed subjects during treatment with placebo.
TLDR
It is suggested that "effective" placebo treatment induces changes in brain function that are distinct from those associated with antidepressant medication, and cordance may be useful for differentiating between medication and placebo responders. Expand
A systematic review comparing the functional neuroanatomy of patients with depression who respond to placebo to those who recover spontaneously: is there a biological basis for the placebo effect in depression?
  • A. Vallance
  • Medicine, Psychology
  • Journal of affective disorders
  • 2007
TLDR
Systematic review of functional neuroimaging studies containing unipolar depressed patients finds recovery from depression in placebo groups correlates with changes in frontal and cingulate cortical activity, although these may also be found in recovery without treatment. Expand
The Biochemical Bases for Reward
TLDR
It is argued that placebo-induced dopamine release in limbic structures, particularly in the nucleus accumbens, could also be a major biochemical substrate for the placebo effect encountered in other medical disorders. Expand
Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain
TLDR
There is little evidence that decreasing the placebo response rate makes it more likely that superiority of active vs. placebo treatment will be demonstrated, and analyses of neuropathic pain clinical trial databases should be conducted to examine factors associated with trial outcomes. Expand
Placebo effects on human μ-opioid activity during pain
TLDR
The results suggest that endogenous opioid release in core affective brain regions is an integral part of the mechanism whereby expectancies regulate affective and nociceptive circuits. Expand
The placebo response in Parkinson's disease. Parkinson Study Group.
TLDR
Although there is clearly a placebo response in PD patients, a review suggests that the variation in placebo response does not correlate with demographic factors such as age, gender, religion, level of education, or duration of PD. Expand
Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson's Disease
TLDR
In vivo evidence is provided for substantial release of endogenous dopamine in the striatum of PD patients in response to placebo, indicating that the placebo effect in PD is powerful and is mediated through activation of the damaged nigrostriatal dopamine system. Expand
Objective changes in motor function during placebo treatment in PD
TLDR
All domains of parkinsonian disability were subject to placebo-associated improvement, with a trend toward more response in bradykinesia and rigidity than in tremor or gait/balance/midline function. Expand
...
1
2
3
4
5
...